Pacira BioSciences Inc. (PCRX)
NASDAQ: PCRXHealthcareDrug Manufacturers - Specialty & GenericUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
PCRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.00B
- P/E (TTM)
- 72.00
- Forward P/E
- 7.27
- EPS (TTM)
- $0.35
- Dividend yield
- None
- 52-week range
- 18.80 – 27.66
- Day range
- 24.99 – 25.99
- Volume / Avg
- 802.73K / 581.50K
- Beta
- —
- Shares outstanding
- 39.86M
- Next earnings
- Nov 5, 2026
52-week range
PCRX stock today
Shares of Pacira BioSciences (PCRX) finished higher on Oct 7 at $25.20, a gain of 1.78% or $0.44 per share, versus the S&P 500's 0.22% decline. Shares are 8.9% below their 52-week high of $27.66, set on Aug 4, 2026 and 34.0% above the 52-week low of $18.80, in the middle of the past year's range. PCRX is down 2.6% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 6.7%.
At 72.0x trailing earnings, Pacira BioSciences trades above the peer-group median of 16.1x. Its forward P/E of 7.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Pacira BioSciences's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Pacira BioSciences
Company profilePacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Frank D. Lee
- Headquarters
- Brisbane, CA
- Employees
- 825
- IPO year
- 2011
- Website
- pacira.com
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$30.11+19.48%
- Strong buy 1
- Buy 4
- Hold 3
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $0.48
Pacira BioSciences peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AMPHAmphastar Pharmaceuticals Inc. | 25.54 | -1.43% | $1.09B | vs PCRX |
| HROWHarrow Inc. | 30.62 | +0.89% | $1.15B | vs PCRX |
| CRONCronos Group Inc. | 3.24 | -1.37% | $1.19B | vs PCRX |
| COLLCollegium Pharmaceutical Inc. | 21.93 | +0.23% | $713.94M | vs PCRX |
| IRWDIronwood Pharmaceuticals Inc. Class A | 3.75 | +3.31% | $619.65M | vs PCRX |
| AQSTAquestive Therapeutics Inc. | 4.62 | +0.22% | $579.86M | vs PCRX |
| EVOEvotec SE ADR | 1.61 | -1.23% | $572.18M | vs PCRX |
| TLRYTilray Brands Inc. | 3.72 | -1.72% | $549.01M | vs PCRX |
Indexes, lists and sector
Appears in lists
Pacira BioSciences stock FAQ
What is Pacira BioSciences's stock price today?
PCRX last traded at $25.20 as of Oct 7, 4:00 PM EDT, up 1.78% on the day. Prices are delayed at least 15 minutes.
When is Pacira BioSciences's next earnings date?
Pacira BioSciences is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $0.48.
What is PCRX's P/E ratio?
PCRX trades at a trailing P/E ratio of 72.00 and a forward P/E of 7.27, compared with a median of 16.1 for its closest peers.
Who is Pacira BioSciences's CEO?
Mr. Frank D. Lee is the chief executive officer of Pacira BioSciences Inc., which has about 825 employees.
What is the PCRX 52-week high?
The 52-week high for PCRX is $27.66 and the 52-week low is $18.80. The stock is currently 8.9% below its high.